X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Lovance intends to use the proceeds from this offering to support the commercial launch of Amtagvi (lifileucel), which is a tumor-derived autologous T-cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Amtagvi
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $211.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 20, 2024
Details:
Amtagvi (lifileucel) is an engineered tumor-infiltrating lymphocyte (TIL) therapy. It is indicated for the treatment of of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody..
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Amtagvi
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Iovance intends to use the proceeds to fund preparations for the commercial launch of LN-144 (lifileucel), when approved and to support ongoing clinical programs including its NSCLC registration-directed study and its frontline advanced melanoma Phase 3 confirmatory trial.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 13, 2023
Details:
Iovance intends to use the proceeds to fund preparations for the commercial launch of LN-144 (lifileucel), when approved and to support ongoing clinical programs including its NSCLC registration-directed study and its frontline advanced melanoma Phase 3 confirmatory trial.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 10, 2023
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
LN-144 (lifileucel) is a tumor infiltrating lymphocyte therapy in combination with pembrolizumab is intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2023
Details:
LN-144 (lifileucel) is an investigational TIL therapy for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy, and targeted BRAF/MEK inhibitor therapy where appropriate.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
LN-144 (lifileucel) is an adoptive cell transfer therapy that utilizes an autologous TIL for the treatment of patients with unresectable or metastatic melanoma, advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
LN-144 (lifileucel), a tumor infiltrating lymphocyte therapy, in patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy, and if BRAF mutation positive, also prior BRAF or BRAF/MEK inhibitor therapy.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
TIL product LN-144 (lifileucel) for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The TIL platform has demonstrated promising clinical data across multiple solid tumors.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
TIL product candidate, lifileucel for metastatic melanoma, has potential to become first approved one-time cell therapy for a solid tumor cancer, also has demonstrated promising clinical data across multiple solid tumors.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Updated data from combination cohort of LN-144 (lifileucel), T lymphocyte replacement, and pembrolizumab in ICI naïve patients (Cohort 1A in the IOV-COM-202 study, n=12) demonstrated an overall response rate (ORR) of 67%.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Successful manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from cryopreserved tumor samples shipped from Australia, may address challenges of longer shipment times and broaden global access.
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2022
Details:
TIL is a first-in-class, one-time administration cell therapy and the first potential BLA for a cell therapy in solid tumors.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
The results from the C-144-01 clinical study, as well as the advancement of lifileucel using a centralized TIL manufacturing process, offer a new opportunity for accessible treatment for the most challenging to treat patients with metastatic melanoma.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
Iovance Biotherapeutics will present poster titled "Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy."
Lead Product(s): Lifileucel,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
Details:
The Company believes that clinical data from its C-144-01 trial supports the potential for lifileucel as a treatment for metastatic melanoma. Iovance and the FDA have reached agreement on the duration of follow up for its pivotal Cohort 4 to support the BLA submission.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: LN-144
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Fund to be used for: potential commercial launch of lifileucel and LN-145, to initiate a program directed at registration of its tumor-infiltrating lymphocyte therapies in non-small cell lung cancer, for the development of its IL-2 analog, IOV-3001.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: DLA Piper
Deal Size: $604.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 04, 2020
Details:
Lifileucel shows a 36.4% overall response rate (n=66) and median duration of response (DOR) was not reached at 17.0 months of median study follow up.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
New interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma will presented at the upcoming ASCO20 Virtual Scientific Program.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Details:
Iovance has completed dosing the last patient in the registration-enabling Cohort 4 of the C-144-01 study of lifileucel in the treatment of patients with advanced melanoma.
Lead Product(s): Lifileucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
